Matinas BioPharma Holdings, Inc. — fact timeline

Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

“April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha”

Matinas BioPharma Holdings, Inc.: Increased authorized shares of common stock from 250,000,000 to 500,000,000 (effective 2025-08-06).

“On August 6, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 250,000,000 shares to 500,000,000 shares. The Certificate of Amendment was approved by the Company’s stockholders at the 2025 annual meeting on June 23, 2025 and became effective upon filing.”

Eric Ende resigned as Chairman of the Board at Matinas BioPharma Holdings, Inc..

“On March 13, 2025, Eric Ende informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that he was resigning as a member of the Board and as Chairman of the Board effective March 14, 2025, due to his other professional obligations.”

Edward Neugeboren was appointed as Director at Matinas BioPharma Holdings, Inc..

“The Board appointed Mr. Neugeboren to serve as a member of the Audit Committee and as Chair of the Compensation Committee.”

Keith Murphy was appointed as Director at Matinas BioPharma Holdings, Inc..

“Effective as of March 11, 2025, the Board, on the recommendation of the Governance Committee, appointed Keith Murphy and Edward Neugeboren directors of the Company to replace Ms. Giordano and Mr. Wikler, respectively.”

Matthew Wikler resigned as Director at Matinas BioPharma Holdings, Inc..

“On February 10, 2025, Matthew Wikler informed the Board that he was resigning from the Board effective February 11, 2025, due to his other professional obligations.”

Natasha Giordano resigned as Director at Matinas BioPharma Holdings, Inc..

“On February 10, 2025, Natasha Giordano informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that she was resigning from the Board effective February 11, 2025, due to her other professional obligations.”

Robin Smith was appointed as Director at Matinas BioPharma Holdings, Inc..

“the Board, on the recommendation of its Nominating and Corporate Governance Committee, appointed Robin Smith director of the Company.”

Herbert Conrad resigned as Director at Matinas BioPharma Holdings, Inc..

“On February 5, 2025, Herbert Conrad informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that he was resigning from the Board effective February 6, 2025, due to retirement.”

Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding other (rules 704).

“January 6, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the NYSE American LLC (“NYSE American”) stating that the Company failed to hold an annual meeting of stockholders during its fiscal year ended December 31, 2024, as required by Section 704 of the NYSE American Company Guide (the “Company Guide”). A copy of the press release that discusses this matter is furnished as Exhibit 99.1 hereto and incorporated herein by reference. The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be li”

Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding other.

“January 6, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the NYSE American LLC (“NYSE American”) stating that the Company failed to hold an annual meeting of stoc”

Matinas BioPharma Holdings, Inc. announced a restructuring (80% workforce reduction).

“Matinas BioPharma Holdings, Inc. (the “Company”) implemented an 80% workforce reduction effective as of October 31, 2024 (the “Reduction in Force”) and ceased all product development activities to conserve cash.”

James Ferguson was terminated as Chief Medical Officer at Matinas BioPharma Holdings, Inc..

“the employment of James Ferguson, M.D., the Company’s Chief Medical Officer, was terminated effective October 31, 2024.”

Matinas BioPharma Holdings, Inc. reported the three months ending March 31, 2024 results: revenue no revenue for the first quarter of 2024, net income net loss for the first quarter of 2024 was $5.8 million, or $0.03 per share, EPS $0.03 per share.

“Matinas BioPharma Holdings, Inc . (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.”

Matinas BioPharma Holdings, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Placement agent to use reasonable best efforts to sell securities; cash fee of 7.0% of aggregate pur (effective 2024-04-02).

“On April 2, 2024, the Company also entered into a placement agent agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).”

Matinas BioPharma Holdings, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at 33,333,334 shares of common stock and warrants to purchase 33,333,334 shares of common stock at offe (effective 2024-04-02).

“On April 2, 2024, Matinas BioPharma Holdings, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).”

Matinas BioPharma Holdings, Inc. reported financial results for for the year and quarter ended December 31, 2023.

“On March 27, 2024, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the year and quarter ended December 31, 2023.”

Matinas BioPharma Holdings, Inc. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split at a ratio in the range of 1-for-2 to 1-for-50 and reduce authorized common shares to 250,000,000 at the 2023-11-01 meeting.

“Our stockholders approved an amendment to our Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio in the range of 1-for-2 to 1-for-50, with such reverse stock split to be effected at such ratio, time and date, if at all, as determined by our Board of Directors in its sole discretion, and simultaneously with the reverse stock split, reduce the total number of authorized shares of common stock to 250,000,000.”

Matinas BioPharma Holdings, Inc. shareholders approved Ratification of the appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-11-01 meeting.

“Our stockholders approved the ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.”

Matinas BioPharma Holdings, Inc. shareholders approved Advisory approval of the compensation of the named executive officers at the 2023-11-01 meeting.

“Our stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”

Matinas BioPharma Holdings, Inc. shareholders approved Election of seven directors to serve until the 2024 annual meeting at the 2023-11-01 meeting.

“Our stockholders elected the following individuals to serve on our board of directors until the annual meeting of shareholders to be held in 2024.”

Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).

“September 21, 2023, Matinas Biopharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the NYSE American LLC (the “NYSE American” or the “Exchange”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide due to its shares of common stock selling for a substantial period of time at a low price per share, which NYSE American determined to be a 30 trading day average price of less than $0.20 per share. The Letter has no immediate effect on the listing or tr”

Matinas BioPharma Holdings, Inc. reported the three and six months ended June 30, 2023 results: revenue no revenue.

“Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.”

Matinas BioPharma Holdings, Inc. reported financial results for the quarter ended March 31, 2023.

“On May 10, 2023, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.”

Matinas BioPharma Holdings, Inc. reported the year ended December 31, 2022 results: revenue $3.2 million, net income $21.0 million, EPS $0.10 per share.

“Revenue for the year ended December 31, 2022 was $3.2 million, which was generated from the research collaboration with BioNTech SE. This compares with revenue for the year ended December 31, 2021 of $33,000, which was generated from the feasibility study agreement with Genentech Inc. Total costs and expenses for 2022 were $27.8 million compared with $24.8 million for 2021. The increase was due primarily to higher research and development expenses reflecting the later stage of the Company’s clinical development programs. Income from selling unused New Jersey net operating losses (NOLs) and research and development tax credits was $3.5 million and $1.3 million for 2022 and 2021, respectively. The net loss attributable to common shareholders for 2022 was $21.0 million, or $0.10 per share, compared with a net loss attributable to common shareholders for 2021 of $23.7 million, or $0.11 per share.”

Matinas BioPharma Holdings, Inc. shareholders approved Ratification of appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2022 at the 2022-11-14 meeting.

“The tabulation of votes with respect to this proposal was as follows: For Against Abstain Broker Non-Votes 126,116,312 468,604 488,493 - -”

Matinas BioPharma Holdings, Inc. shareholders approved Advisory vote on compensation of the Company's named executive officers at the 2022-11-14 meeting.

“The tabulation of votes with respect to this proposal was as follows: For Against Abstain Broker Non-Votes 56,522,115 6,902,448 1,110,330 62,538,516”

Matinas BioPharma Holdings, Inc. shareholders approved Election of directors to serve on the board of directors until the annual meeting of shareholders to be held in 2023 at the 2022-11-14 meeting.

“The tabulation of votes with respect to the election of such directors was as follows: AUTHORITY BROKER FOR WITHELD NON-VOTE Herbert Conrad 59,278,388 5,256,505 62,538,516 Kathryn Corzo 59,698,087 4,836,806 62,538,516 Jerome D. Jabbour 60,041,871 4,493,022 62,538,516 Eric Ende 59,832,977 4,701,916 62,538,516 Natasha Giordano 59,185,407 5,349,486 62,538,516 James Scibetta 60,052,024 4,482,869 62,538,516 Matthew Wikler 60,446,318 4,088,575 62,538,516”

Matinas BioPharma Holdings, Inc. reported the third quarter ended September 30, 2022 results: revenue $1.1 million, net income $5.5 million, EPS $0.03 per share.

“For the third quarter of 2022, net loss attributable to common shareholders was $5.5 million, or a net loss of $0.03 per share (basic and diluted), compared to a net loss attributable to common shareholders of $6.8 million, or a net loss of $0.03 per share (basic and diluted), for the same period in 2021. The reduced loss resulted from the Company recording $1.1 million in revenue from its research collaboration with BioNTech SE, along with a slight decrease in operating expenses year over year.”

Thomas Hoover was appointed as Chief Business Officer at Matinas BioPharma Holdings, Inc..

“On December 6, 2021, Matinas BioPharma Holdings, Inc. (the “Company” or “Matinas”) announced that Thomas Hoover, age 52, has been appointed as the Company’s Chief Business Officer.”

Patrick LePore resigned as Director at Matinas BioPharma Holdings, Inc..

“On September 17, 2021, director Patrick LePore informed the Board of Directors (the “Board”) of Matinas BioPharma Holdings, Inc. (the “Company”) that he will not stand for re-election to the Board at the upcoming annual meeting of stockholders, which will be held on November 1, 2021 (the “Annual Meeting”).”